RT Journal Article SR Electronic T1 Trends in serotype distribution and disease severity in adults hospitalised with Streptococcus pneumoniae infection in Bristol and Bath: a retrospective cohort study, 2006-2022 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.03.30.23287917 DO 10.1101/2023.03.30.23287917 A1 Hyams, Catherine A1 Challen, Robert A1 Hettle, David A1 Amin-Chowdhury, Zahin A1 Grimes, Charli A1 Ruffino, Gabriella A1 Conway, Rauri A1 Heath, Robyn A1 North, Paul A1 Malin, Adam A1 Maskell, Nick A A1 Williams, Philip A1 Martin Williams, O. A1 Ladhani, Shamez N A1 Danon, Leon A1 Finn, Adam YR 2023 UL http://medrxiv.org/content/early/2023/07/13/2023.03.30.23287917.abstract AB Ongoing surveillance is essential to inform policy decisions and monitor serotype replacement following pneumococcal conjugate vaccination (PCV) deployment. We report serotype and disease severity trends in this retrospective cohort of hospitalised adults in Bristol-Bath, 2006-22. Of 1686 invasive pneumococcal disease (IPD) cases, 1501 (89.0%) had known serotype. We also identified 2033/3719 cases of non-IPD. IPD declined sharply during the early COVID-19 pandemic. Over 2022 it gradually returned to pre-pandemic levels. Disease severity also changed throughout this period: CURB65 severity and inpatient mortality decreased whilst ICU admissions increased. PCV7 and PCV13-serotype IPD decreased from 2006-09 to 2021-22. However, significant residual PCV13-serotype IPD remains, representing 21.7% [15.5-29.6] of 2021-22 cases, highlighting that significant adult PCV-serotype disease still occurs despite 17-years of paediatric PCV usage in the UK. We found increased proportions of serotype 3 and 8 IPD, whilst 19F and 19A re-emerged. In 2020-22, 68.2% IPD cases were potentially covered by PCV20.Article Summary We observed significant serotype shifts but perseverance and re-emergence of some serotypes covered by PCVs over this 17-year retrospective study, which found considerable adult pneumococcal disease attributable to PCV-serotypes despite high uptake of paediatric PCV.Competing Interest StatementCH is Principal Investigator of the AvonCAP study which is an investigator-led University of Bristol study funded by Pfizer. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and was, until December 2022, chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare.Funding StatementCH was funded by the National Institute for Health Research [NIHR Academic Clinical Fellowship (ACF-2015-25-002). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority, UK (IRAS 265437).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. Therefore, individual participant data and a data dictionary is not available to other researchers.